Lord, Abbett & Co
TERN

Lord, Abbett & Co’s Terns Pharmaceuticals TERN Stock Holding History

Lord, Abbett & Co’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148M Buy
2,812,938
+100,539
+4% +$4.13M 0.48% 53
2025
Q4 		$110M Buy
+2,712,399
New +$62.7M 0.34% 80

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lord, Abbett & Co's TERN Position: Q1 2026 in Review

Lord, Abbett & Co increased its Terns Pharmaceuticals (TERN) stake by 3.7% in Q1 2026, buying an estimated $4.13M and bringing the position to 2,812,938 shares worth $148M. The position accounts for 0.48% of the portfolio, ranked #53.

Lord, Abbett & Co first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Lord, Abbett & Co held 2,812,938 shares of Terns Pharmaceuticals worth $148M as of Q1 2026.
  • Lord, Abbett & Co bought 100,539 Terns Pharmaceuticals shares in Q1 2026, an estimated $4.13M.
  • Terns Pharmaceuticals made up 0.48% of Lord, Abbett & Co's portfolio in Q1 2026, its #53 holding.
  • Lord, Abbett & Co first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.